Investigational drug · Phase 3
L606
Also called: Treprostinil Liposome
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pulmonary Hypertension Due to Lung Disease (Disorder).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "L606"
First trial start
2026
Apr 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "L606", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Hypertension Due to Lung Disease (Disorder)
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "L606" as an intervention, largest first.
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILDPivotal-lookingRecruiting
Liquidia Technologies, Inc.Industry
NCT07285655 · 344 participants (planned) · Start Apr 23, 2026 · Primary completion Jul 2029
Drug: L606; Placebo · For: Pulmonary Hypertension Due to Lung Disease (Disorder)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 44 sites in all
- Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606Completed
Pharmosa Biopharm Inc.Industry
NCT04041648 · 52 participants · Start Nov 9, 2018 · Primary completion Sep 20, 2019
Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug · For: Pulmonary Arterial Hypertension
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Clinical utility of vitamin d testing: an evidence-based analysis.
· Ont Health Technol Assess Ser 2010
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.